Cargando…

LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS

BACKGROUND: The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the NordiNet® International Outcome Study (NordiNet® IOS) were large-scale, non-interventional studies intended to gather long-term data on the effectiveness and safety of Norditropin® (somatropin) treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ross, Judith L, Fridman, Moshe, Kelepouris, Nicky, Murray, Kristine, Krone, Nils Peter, Polak, Michel, Nedjatian, Navid, Rohrer, Tilman Robert, Pietropoli, Alberto, Lawrence, Neil, Backeljauw, Philippe Ferdinand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Pediatric Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9625391/ http://dx.doi.org/10.1210/jendso/bvac150.1226

Ejemplares similares

Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER
por: Sävendahl, Lars, et al.
Publicado: (2021)

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet(®) IOS and Answer Program
por: Backeljauw, Philippe, et al.
Publicado: (2023)

Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet(®) IOS and ANSWER Program
por: Sävendahl, Lars, et al.
Publicado: (2019)

Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis
por: Ross, Judith, et al.
Publicado: (2023)

PMON60 Growth Hormone (GH) Replacement Therapy (GHRT) in Patients with Adult GH Deficiency (AGHD) Aged ≥60 Years: Data from NordiNet® IOS and the ANSWER Program
por: Biller, Beverly, et al.
Publicado: (2022)

Effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age: Long-Term Data From NordiNet® International Outcome Study (IOS) and ANSWER Program
por: Juul, Anders, et al.
Publicado: (2021)

Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER
por: Biller, Beverly M K, et al.
Publicado: (2023)

Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program
por: Biller, Beverly M. K., et al.
Publicado: (2021)

Outcomes in children treated with growth hormone for Prader-Willi syndrome: data from the ANSWER Program® and NordiNet® International Outcome Study
por: Angulo, Moris, et al.
Publicado: (2020)

Abstract 2: Effectiveness and safety of early growth hormone treatment in children born small for gestational age: Long-term data from NordiNet® International Outcome Study (IOS) and ANSWER program
por: Ranjan, K M, et al.
Publicado: (2022)

SAT-282 Outcomes in Children Treated with Growth Hormone for Prader-Willi Syndrome: Data from the Answer® Program and Nordinet® International Outcome Study (IOS)
por: Angulo, Moris, et al.
Publicado: (2019)

Cardiovascular safety of growth hormone treatment in Noonan syndrome: real-world evidence
por: Romano, Alicia, et al.
Publicado: (2021)

Early Growth Hormone Initiation Leads to Favorable Long-Term Growth Outcomes in Children Born Small for Gestational Age
por: Juul, Anders, et al.
Publicado: (2022)

Early growth hormone treatment start in childhood growth hormone deficiency improves near adult height: analysis from NordiNet® International Outcome Study
por: Polak, Michel, et al.
Publicado: (2017)

CORRIGENDUM for “Treatment of Children With GH in the United States and Europe: Long-Term Follow-Up From NordiNet® IOS and ANSWER Program”
Publicado: (2020)

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status
por: Jorge, Alexander A L, et al.
Publicado: (2022)

Noonan syndrome and Turner syndrome patients respond similarly to 4 years’ growth-hormone therapy: longitudinal analysis of growth-hormone-naïve patients enrolled in the NordiNet® International Outcome Study and the ANSWER Program
por: Lee, Peter A., et al.
Publicado: (2015)

Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studies
por: Höybye, Charlotte, et al.
Publicado: (2022)

LBMON138 Leg Tumeo: Is It Neuroendocrine Tumor?
por: Priyadarshini, Shista, et al.
Publicado: (2022)

LBMON273 Not All Men Are Created Equal
por: van Rooyen, Desmaré, et al.
Publicado: (2022)

The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)
por: Höybye, Charlotte, et al.
Publicado: (2013)

LBMON174 Germline Molecular Genetics Of Pituitary Adenomas
por: Alzahrani, Ali, et al.
Publicado: (2022)

LBMON175 Nadir Growth Hormone Concentrations In Patients With Acromegaly Relate To Disease Activity, Glucose Metabolism, BMI And Sex
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2022)

LBMON185 Isthmin-1 As A Modulator Of Metabolic Health
por: Zhao, Meng, et al.
Publicado: (2022)

LBMON137 Don't Be Fooled By Normotension Pheo Could Be The Potential
por: Idriss, Setana, et al.
Publicado: (2022)

Shared Decision-Making in Growth Hormone Therapy—Implications for Patient Care
por: Acerini, Carlo L., et al.
Publicado: (2018)

LBMON231 Virilization Secondary To Androgen Producing Ovarian Serous Cystadenoma
por: De Guzman, Vernon Joseph, et al.
Publicado: (2022)

LBMON237 Predictors Of Postmenarchal Progression Of Pcos Phenotypes In At-risk Girls
por: Torchen, Laura C, et al.
Publicado: (2022)

LBMON272 Chromatoid Bodies In The Regulation Of Spermatogenesis: Novel Role Of Grth
por: Anbazhagan, Rajakumar, et al.
Publicado: (2022)

LBMON141 Macroorchidism In A Patient With A Functional Gonadotroph Macroadenoma
por: Chale-Matsau, Bettina, et al.
Publicado: (2022)

THU008 Coverage Of Education And Training Of Traumatic Brain Injury-induced Growth Hormone Deficiency In US Endocrinology Fellowship Programs
por: Ji Yuen, Kevin Choong, et al.
Publicado: (2023)

Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients’ Perspective
por: Hoffman, Andrew R, et al.
Publicado: (2022)

LBMON299 Aldosterone Production Is Regulated By Gap Junctions In Human Adrenal Cells
por: Goodchild, Emily, et al.
Publicado: (2022)

LBMON196 A Randomized Controlled Trial Of Vosoritide In Infants And Toddlers With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2022)

Directed and elliptic flow in $^{197}Au+^{197}Au$ at intermediate energies
por: Lukasik, J, et al.
Publicado: (2005)

LBMON233 Hormonebayes: A Novel Bayesian Toolbox For Analysis Of Pulsatile Hormone Dynamics
por: Voliotis, Margaritis, et al.
Publicado: (2022)

LBMON236 Investigating The Effect Of Social Vulnerability Index On Fibroid Recurrence And Metabolic Dysfunction
por: Allen, Antoinette, et al.
Publicado: (2022)

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
por: Miller, Bradley, et al.
Publicado: (2022)

LBMON172 Impact Of Photoperiodic Green Light During Incubation On Change Hormone In The Embryo Of Chicken
por: Abdulateef, Salwan, et al.
Publicado: (2022)

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()
por: Zaman, Shadia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3ceu5h08gf1964sfsbrdsme7kk